Equity research analysts expect Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN – Get a rating) to report earnings of ($1.82) per share for the current quarter, according to Zacks. Six analysts released earnings estimates for Biohaven Pharmaceutical, with the lowest EPS estimate at $3.25 and the highest at $0.01. Biohaven Pharmaceutical reported earnings per share of ($4.21) in the same quarter last year, suggesting a positive year-over-year growth rate of 56.8%. The company is due to release its next earnings report on Monday, May 9.
According to Zacks, analysts expect Biohaven Pharmaceutical to report full year earnings of ($5.89) per share for the current year, with EPS estimates ranging from ($8.51) to ($2 $.70). For the next fiscal year, analysts expect the company to report earnings of ($2.35) per share, with EPS estimates ranging from ($5.84) to $3.16. Zacks’ earnings per share calculations are an average average based on a survey of sell-side analysts who follow Biohaven Pharmaceutical.
Biohaven Pharmaceutical (NYSE: BHVN – Get a rating) last released its quarterly results on Thursday, February 24. The company reported ($3.01) EPS for the quarter, missing Thomson Reuters consensus estimate of ($2.04) by ($0.97). The company posted revenue of $190.01 million for the quarter, compared to $175.54 million expected by analysts. The company’s revenue for the quarter increased 441.1% year over year. During the same quarter of the previous year, the firm had posted ($3.62) earnings per share.
A number of research companies have weighed in on BHVN recently. HC Wainwright reaffirmed a “buy” rating and set a price target of $160.00 on shares of Biohaven Pharmaceutical in a Friday, Jan. 7 research report. Cantor Fitzgerald raised his price target on Biohaven Pharmaceutical from $165.00 to $177.00 and gave the company an “overweight” rating in a Wednesday, November 10 report. Mizuho raised his price target on Biohaven Pharmaceutical shares from $144.00 to $154.00 and gave the stock a “buy” rating in a research note on Thursday. Morgan Stanley raised its price target on Biohaven Pharmaceutical shares from $145.00 to $148.00 and gave the company an “equal weight” rating in a research note on Friday, January 7. Finally, UBS Group raised its price target on Biohaven Pharmaceutical shares from $150.00 to $160.00 in a Tuesday, January 4, report. Three investment analysts gave the stock a hold rating and eight gave the company a buy rating. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $148.45.
In other Biohaven Pharmaceutical news, an insider Elysee Stock sold 21,919 shares of the company in a trade dated Wednesday, December 15. The stock was sold at an average price of $105.49, for a total transaction of $2,312,235.31. The sale was disclosed in a legal filing with the SEC, available at this link. Additionally, CAO George C. Clark sold 1,915 shares of the company in a trade on Monday, Dec. 20. The stock was sold at an average price of $123.84, for a total transaction of $237,153.60. Disclosure of this sale can be found here. Insiders sold a total of 80,209 shares of the company worth $8,735,608 in the past ninety days. 15.20% of the shares are held by insiders.
A number of hedge funds have recently changed their positions in the business. Capital World Investors increased its stake in shares of Biohaven Pharmaceutical by 1.9% in the fourth quarter. Capital World Investors now owns 6,178,009 shares of the company worth $851,391,000 after acquiring an additional 115,628 shares during the period. BlackRock Inc. raised its position in Biohaven Pharmaceutical by 0.6% in the fourth quarter. BlackRock Inc. now owns 4,635,280 shares of the company worth $638,787,000 after purchasing an additional 28,207 shares during the period. Stifel Financial Corp increased its stake in Biohaven Pharmaceutical by 1.9% during the fourth quarter. Stifel Financial Corp now owns 3,049,995 shares of the company valued at $420,319,000 after buying an additional 55,650 shares last quarter. Marshall Wace LLP increased its stake in shares of Biohaven Pharmaceutical by 3.0% in the 4th quarter. Marshall Wace LLP now owns 2,798,457 shares of the company worth $385,657,000 after purchasing an additional 80,272 shares in the last quarter. Finally, State Street Corp increased its stake in shares of Biohaven Pharmaceutical by 11.0% in the fourth quarter. State Street Corp now owns 1,647,694 shares of the company valued at $227,069,000 after purchasing an additional 162,764 shares last quarter. 91.73% of the shares are held by institutional investors.
Shares of NYSE:BHVN opened at $113.10 on Monday. The company has a 50-day moving average price of $128.58 and a 200-day moving average price of $128.36. Biohaven Pharmaceutical has a 12-month low of $62.57 and a 12-month high of $151.51. The company has a market capitalization of $7.98 billion, a price-earnings ratio of -8.65 and a beta of 1.08.
Biohaven Pharmaceutical Company Profile (Get a rating)
Biohaven Pharmaceutical Holding Co Ltd. is a clinical-stage biopharmaceutical company, dedicated to the research and development of late-stage product candidates targeting neurological diseases, including rare diseases. It is focused on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-linked peptide receptor antagonists and glutamate modulators.
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Biohaven Pharmaceutical right now?
Before you consider Biohaven Pharmaceutical, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and Biohaven Pharmaceutical didn’t make the list.
Although Biohaven Pharmaceutical currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here